Avapritinib
- Generic Name
- Avapritinib
- Brand Names
- Ayvakit, Ayvakyt
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27FN10
- CAS Number
- 1703793-34-3
- Unique Ingredient Identifier
- 513P80B4YJ
- Background
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis. It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares...
- Indication
Avapritinib is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
...
- Associated Conditions
- Advanced Systemic Mastocytosis (AdvSM), Aggressive Systemic Mastocytosis, Indolent Systemic Mastocytosis, Mast Cell Leukemia (MCL), Metastatic Gastrointestinal Stromal Tumor (GIST), Systemic Mastocytosis With an Associated Hematological Neoplasm, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
Blueprint Medicines' SWOT analysis: stock's potential in precision oncology
Blueprint Medicines, valued at $6.2B, focuses on targeted therapies for genomically defined cancers and rare diseases. With Ayvakit as its lead product, the company reported $128.2M in Q3 2024 revenues, surpassing expectations. Ayvakit shows significant efficacy in treating Advanced Systemic Mastocytosis, with an 81% risk reduction in death. The company's strong cash position and innovative pipeline, including BLU-222 and BLU-808, position it for growth. However, negative EPS forecasts and market competition pose challenges.
Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis
ASH data show AYVAKIT® (avapritinib) improves survival in advanced systemic mastocytosis (SM) patients, with bone density improvements and undetected KIT mutations identified by ultra-sensitive testing. Blueprint Medicines presented these findings at the 66th ASH Annual Meeting.
Game-Changing Results in Systemic Mastocytosis Treatment
ASH data show AYVAKIT® (avapritinib) improves survival in advanced systemic mastocytosis (SM) patients, with bone density improvements and undetected KIT mutations identified by ultra-sensitive testing.
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic
ASH data show AYVAKIT® (avapritinib) improves survival in advanced systemic mastocytosis (SM) patients, with bone density improvements and undetected KIT mutations identified by ultra-sensitive testing. Blueprint Medicines' HARBOR trial aims to assess disease-modifying impact.
Blueprint Medicines' SWOT analysis: stock outlook amid strong Ayvakit sales
Blueprint Medicines, a biopharmaceutical company, has strong financial performance with Ayvakit, raising 2024 sales guidance to $435-$450 million. Its pipeline includes Ayvakit for systemic mastocytosis and BLU-222 for HR+/HER2- breast cancer. Despite risks like pricing pressure and competition, future growth opportunities include Ayvakit's expansion and potential partnerships for BLU-222.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath